On May 14, 2025, Neumora Therapeutics, Inc. was notified by Nasdaq that it failed to meet the $1.00 minimum bid price requirement for continued listing, giving the company until November 10, 2025, to regain compliance or risk delisting. The company plans to consider a reverse stock split to address this issue, pending stockholder approval on May 28, 2025.